Abstract: To compare the clinical effect of chemotherapy using the protein-binding Abraxane with that using Docetaxel in the neoadjuvant therapy of breast cancer. Methods: Neoadjuvant chemotherapy with TEC regimen was administered in 56 patients. Twenty six patients were treated with Abraxane (study group ), whereas 30 patients were treated with Docetaxel ( control group ). Surgery was conducted after 4 courses of the regimen, and the therapeutic effect was appraised. Results: The pathological complete remission ( pCR ) rate was 38.5% and 10% in the study and control groups, respectively ( P  < 0.05 ). The total effective rate ( clinical complete remission plus clinical partial response ) was 88.5% and 73.3% in the Abraxane and Docetaxel groups, respectively ( P > 0.05 ). Conclusion: The pCR rate is higher in breast cancer patients treated with albumin-binding Abraxane compared with those who were administered with Docetaxel. The total effective rate may also be higher in the study group than in the control group.